無輸血醫療的成本效益
骨科
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H). （開啟新視窗）
來源: J Bone Joint Surg Am 2013;95(21):1969-74.
檢索: PubMed 24196467
DOI碼: 10.2106/JBJS.L.00908
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K). （開啟新視窗）
來源: J Bone Joint Surg Am 2013;95(21):1961-8.
檢索: PubMed 24196466
DOI碼: 10.2106/JBJS.L.00907
Multimodal patient blood management program based on a three-pillar strategy: a systematic review and meta-analysis. （開啟新視窗）
來源: Ann Surg 2019;269(5):794-804.
檢索: PubMed 30418206
DOI碼: 10.1097/SLA.0000000000003095
Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. （開啟新視窗）
來源: Spine 2009;34(19):2096-103.
檢索: PubMed 19730217
DOI碼: 10.1097/BRS.0b013e3181b1fab2
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty. （開啟新視窗）
來源: J Orthop Surg 2017;25(1):2309499016684725.
檢索: PubMed 28176599
DOI碼: 10.1177/2309499016684725
An evaluation of the use of topical tranexamic acid in total knee arthroplasty. （開啟新視窗）
來源: J Arthroplasty 2013;28(8 Suppl):74-7.
檢索: PubMed 24034510
DOI碼: 10.1016/j.arth.2013.06.037
Hemostatic techniques reduce hospital stay following multilevel posterior cervical spine surgery. （開啟新視窗）
來源: J Bone Joint Surg Am 2012;94(21):1952-8.
檢索: PubMed 23138237
DOI碼: 10.2106/JBJS.K.00632
Comparing ε-aminocaproic acid and tranexamic acid in reducing postoperative transfusions in total knee arthroplasty. （開啟新視窗）
來源: J Knee Surg 2017;30(5):460-6.
檢索: PubMed 27699724
DOI碼: 10.1055/s-0036-1593362
Process improvement project using tranexamic acid is cost-effective in reducing blood loss and transfusions after total hip and total knee arthroplasty. （開啟新視窗）
來源: J Arthroplasty 2017;32(8):2375-80.
檢索: PubMed 28343823
DOI碼: 10.1016/j.arth.2017.02.068
Comparing cost, efficacy, and safety of intravenous and topical tranexamic acid in total hip and knee arthroplasty. （開啟新視窗）
來源: Am J Orthop 2016;45(7):E439-43.
檢索: PubMed 28005108
Clinical and cost effectiveness-related aspects of retransfusion in total hip and knee arthroplasty. （開啟新視窗）
來源: Ortop Traumatol Rehabil 2012;14(5):421-8.
檢索: PubMed 23208933
DOI碼: 10.5604/15093492.1016367
The safety, efficacy, and cost-effectiveness of intraoperative cell salvage in metastatic spine tumor surgery. （開啟新視窗）
來源: Spine J 2017;17(7):977-82.
檢索: PubMed 28323241
DOI碼: 10.1016/j.spinee.2017.03.004
Effect of tranexamic acid on transfusion rates following total joint arthroplasty: a cost and comparative effectiveness analysis. （開啟新視窗）
來源: Orthop Clin North Am 2017;48(2):109-15.
檢索: PubMed 28336035
DOI碼: 10.1016/j.ocl.2016.12.001
Saving blood and reducing costs: updating blood transfusion practice in lower limb arthroplasty. （開啟新視窗）
來源: Ir Med J 2018;111(4):730.
檢索: PubMed 30465599
Methods of bloodless care, clinical outcomes, and costs for adult patients who decline allogeneic transfusions. （開啟新視窗）
來源: Anesth Analg 2022;135(3):576-85.
檢索: PubMed 35977366
DOI碼: 10.1213/ANE.0000000000006114
Radiofrequency bipolar hemostatic sealer reduces blood loss, transfusion requirements, and cost for patients undergoing multilevel spinal fusion surgery: a case control study. （開啟新視窗）
來源: J Orthop Surg Res 2014;9:50.
檢索: PubMed 24997589
DOI碼: 10.1186/s13018-014-0050-2
Tranexamic acid decreases blood loss after total shoulder arthroplasty. （開啟新視窗）
來源: J Shoulder Elbow Surg 2016;25(4):614-8.
檢索: PubMed 26652697
DOI碼: 10.1016/j.jse.2015.09.014
Restrictive versus liberal red blood cell transfusion strategy after hip surgery: a decision model analysis of healthcare costs. （開啟新視窗）
來源: Transfusion 2017;57(2):357-66.
檢索: PubMed 28019009
DOI碼: 10.1111/trf.13936
Economic impact of tranexamic acid in healthy patients undergoing primary total hip and knee arthroplasty. （開啟新視窗）
來源: J Arthroplasty 2013;28(8 Suppl):137-9.
檢索: PubMed 23886409
DOI碼: 10.1016/j.arth.2013.04.054
Cell saver for adult spinal deformity surgery reduces cost. （開啟新視窗）
來源: Spine Deform 2017;5(4):272-6.
檢索: PubMed 28622903
DOI碼: 10.1016/j.jspd.2017.01.005
Tranexamic acid in patients with cancer undergoing endoprosthetic reconstruction: a cost analysis. （開啟新視窗）
來源: J Am Acad Orthop Surg 2021;29(22):961-9.
檢索: PubMed 34570739
DOI碼: 10.5435/JAAOS-D-20-00971
Topically applied epsilon-aminocaproic acid reduces blood loss and length of hospital stay after total knee arthroplasty. （開啟新視窗）
來源: Orthopedics 2017;40(6):e1044-9.
檢索: PubMed 28968480
DOI碼: 10.3928/01477447-20170925-07
Does tranexamic acid reduce blood transfusion cost for primary total hip arthroplasty? A case-control study. （開啟新視窗）
來源: J Arthroplasty 2015;30(2):192-5.
檢索: PubMed 25534861
DOI碼: 10.1016/j.arth.2014.08.020
Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery. （開啟新視窗）
來源: Orthop Traumatol Surg Res 2012;98(5):477-83.
檢索: PubMed 22854336
DOI碼: 10.1016/j.otsr.2012.05.002
Using tranexamic acid for an additional 24 hours postoperatively in hip and knee arthroplasty saves money: a cost analysis from the TRAC-24 randomized control trial. （開啟新視窗）
來源: Bone Jt Open 2022;3(7):536-42.
檢索: PubMed 35816170
DOI碼: 10.1302/2633-1462.37.BJO-2021-0213.R1
Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. （開啟新視窗）
來源: Br J Anaesth 2012;108(6):943-52.
檢索: PubMed 22593128
DOI碼: 10.1093/bja/aes135
Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. （開啟新視窗）
來源: Transfusion 2017;57(6):1347-58.
檢索: PubMed 28150313
DOI碼: 10.1111/trf.14006
Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs. （開啟新視窗）
來源: Br J Anaesth 2007;99(6):794-800.
檢索: PubMed 17928302
DOI碼: 10.1093/bja/aem266
A safe, simple and cost-effective protocol for blood transfusion in primary total knee replacement. （開啟新視窗）
來源: Ann R Coll Surg Engl 2004;86(4):260-2.
檢索: PubMed 15239867
DOI碼: 10.1308/147870804551
Are allogeneic transfusions decreasing in total knee arthroplasty patients? National Inpatient Sample 2009-2013. （開啟新視窗）
來源: J Arthroplasty 2018;33(6):1705-12.
檢索: PubMed 29352682
DOI碼: 10.1016/j.arth.2017.12.014
Transfusion cost savings with tranexamic acid in primary total knee arthroplasty from 2009 to 2012. （開啟新視窗）
來源: J Arthroplasty 2015;30(3):365-8.
檢索: PubMed 25458093
DOI碼: 10.1016/j.arth.2014.10.008
The cost of post-operative shed blood salvage after total knee arthroplasty: an analysis of 1,093 consecutive procedures. （開啟新視窗）
來源: Blood Transfus 2013;11(2):260-71.
檢索: PubMed 23149145
DOI碼: 10.2450/2012.0139-12
Cost of post-operative intravenous iron therapy in total lower limb arthroplasty: a retrospective, matched cohort study. （開啟新視窗）
來源: Blood Transfus 2014;12(1):40-9.
檢索: PubMed 24120595
DOI碼: 10.2450/2013.0088-13
Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. （開啟新視窗）
來源: Transfusion 2011;51(1):118-24.
檢索: PubMed 20624257
DOI碼: 10.1111/j.1537-2995.2010.02783.x
Comparative risk of transfusion and incremental total hospitalization cost for primary unilateral, bilateral, and revision total knee arthroplasty procedures. （開啟新視窗）
來源: J Arthroplasty 2016;31(3):583-589.e1.
檢索: PubMed 26699673
DOI碼: 10.1016/j.arth.2015.10.013
The efficacy, safety, and cost-effectives of combined administration of intravenous and local tranexamic acid in the management of patients undergoing primary total hip arthroplasty: a prospective, blinded and randomized clinical study. （開啟新視窗）
來源: Acta Orthop Traumatol Turc 2021;55(5):422-7.
檢索: PubMed 34730529
DOI碼: 10.5152/j.aott.2021.20397
Blood loss control with two doses of tranexamic acid in a multimodal protocol for total knee arthroplasty. （開啟新視窗）
來源: Open Orthop J 2011;5:44-8.
檢索: PubMed 21552468
DOI碼: 10.2174/1874325001105010044
ONTraC: A 20-year history of a successfully coordinated provincewide Patient Blood Management Program: lessons learned and goals achieved. （開啟新視窗）
來源: Anesth Analg 2022;135(3):448-58.
檢索: PubMed 35977355
DOI碼: 10.1213/ANE.0000000000006065
Cost analysis of tranexamic acid in anemic total joint arthroplasty patients. （開啟新視窗）
來源: J Arthroplasty 2016;31(3):579-82.
檢索: PubMed 26601635
DOI碼: 10.1016/j.arth.2015.10.001
Intravenous administration of tranexamic acid effectively reduces blood loss in primary total knee arthroplasty in a 610-patient consecutive case series. （開啟新視窗）
來源: Transfusion 2016;56(2):466-71.
檢索: PubMed 26509250
DOI碼: 10.1111/trf.13354
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. （開啟新視窗）
來源: BMJ 2014;349:g4829.
檢索: PubMed 25116268
DOI碼: 10.1136/bmj.g4829
One intraoperative dose of tranexamic acid for patients having primary hip or knee arthroplasty. （開啟新視窗）
來源: Clin Orthop Relat Res 2010;468(7):1905-11.
檢索: PubMed 20063079
DOI碼: 10.1007/s11999-009-1217-8
Pharmacologic hemostatic agents in total joint arthroplasty--a cost-effectiveness analysis. （開啟新視窗）
來源: J Arthroplasty 2018;33(7):2092-9.e9.
檢索: PubMed 29605152
DOI碼: 10.1016/j.arth.2018.02.068
Efficacy and cost-effectiveness of cell saving blood autotransfusion in adult lumbar fusion. （開啟新視窗）
來源: Transfus Med 2009;19(4):202-6.
檢索: PubMed 19706137
DOI碼: 10.1111/j.1365-3148.2009.00929.x
Improved patient blood management and cost saving in hip replacement surgery through the implementation of pre-operative Sucrosomial® iron supplementation: a quality improvement assessment study. （開啟新視窗）
來源: Int Orthop 2019;43(1):39-46.
檢索: PubMed 30232527
DOI碼: 10.1007/s00264-018-4149-7
Use of a fibrin sealant within a blood-saving protocol in patients undergoing revision hip arthroplasty: effects on post-operative blood transfusion and healthcare-related cost analysis. （開啟新視窗）
來源: Int Orthop 2019;43(12):2707-14.
檢索: PubMed 30671601
DOI碼: 10.1007/s00264-019-04291-4
Use of tranexamic acid is a cost effective method in preventing blood loss during and after total knee replacement. （開啟新視窗）
來源: J Orthop Surg Res 2011;6:22.
檢索: PubMed 21600028
DOI碼: 10.1186/1749-799X-6-22
Increased hospital costs associated with red blood cell transfusion. （開啟新視窗）
來源: Transfusion 2015;55(5):1082-9.
檢索: PubMed 25488623
DOI碼: 10.1111/trf.12958
Cost benefit analysis of topical tranexamic acid in primary total hip and knee arthroplasty. （開啟新視窗）
來源: J Arthroplasty 2014;29(8):1512-5.
檢索: PubMed 24630599
DOI碼: 10.1016/j.arth.2014.01.031
Clinical and budget impact of treating preoperative anemia in major orthopedic surgery--a retrospective observational study. （開啟新視窗）
來源: J Arthroplasty 2020;35(11):3084-8.
檢索: PubMed 32654943
DOI碼: 10.1016/j.arth.2020.06.018
Blood loss and cost-effectiveness of oral vs intravenous tranexamic acid in primary total hip arthroplasty: a randomized clinical trial. （開啟新視窗）
來源: Thromb Res 2018;171:143-8.
檢索: PubMed 30312799
DOI碼: 10.1016/j.thromres.2018.10.006
Incidence and costs of bleeding-related complications in French hospitals following surgery for various diagnoses. （開啟新視窗）
來源: BMC Health Serv Res 2013;13:186.
檢索: PubMed 23692862
DOI碼: 10.1186/1472-6963-13-186
The effectiveness of reinfusion after total knee replacement. A prospective randomised controlled study. （開啟新視窗）
來源: Int Orthop 2007;31(3):303-8.
檢索: PubMed 16810542
DOI碼: 10.1007/s00264-006-0173-0
Efficacy and safety of tranexamic acid in total hip replacement: a PRISMA-compliant meta-analysis of 25 randomized controlled trials. （開啟新視窗）
來源: Medicine 2017;96(52):e9552.
檢索: PubMed 29384974
DOI碼: 10.1097/MD.0000000000009552